In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope

Frontiers in Neuroscience
Tijana BojićSanja Glisic

Abstract

Neurocardiovascular diseases (NCVD) are the leading cause of death in the developed world and will remain so till 2020. In these diseases the pathologically changed nervous control of cardiovascular system has the central role. The actual NCV syndromes are neurogenic hypertension, representing the sympathetically mediated disorder, and vasovagal syncope, which is the vagally mediated disorders. Vasovagal syncope, the disease far from its etiological treatment, could benefit from recruiting and application of antimuscarinic drugs used in other parasympathetic disorders. The informational spectrum method (ISM), a method widely applied for the characterization of protein-protein interactions in the field of immunology, endocrinology and anti HIV drug discovery, was applied for the first time in the analysis of neurogenic hypertension and vasovagal syncope therapeutic targets. In silico analysis revealed the potential involvement of apelin in neurogenic hypertension. Applying the EIIP/ISM bioinformatics concept in investigation of drugs for treatment of vasovagal syncope suggests that 78% of tested antimuscarinic drugs could have anti vasovagal syncope effect. The presented results confirm that ISM is a promissing method for invest...Continue Reading

References

Apr 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S H Northrup, H P Erickson
May 1, 1985·IEEE Transactions on Bio-medical Engineering·V VeljkovićD Lalović
Aug 15, 1996·The American Journal of Cardiology·T M LeeY T Lee
Nov 24, 1999·European Heart Journal·M SantiniV Guido
Mar 23, 2004·Nucleic Acids Research·Robert C Edgar
Feb 20, 2007·Current Medicinal Chemistry·V VeljkovicU Dietrich
Nov 9, 2007·Matrix Biology : Journal of the International Society for Matrix Biology·Roberto DolianaAlfonso Colombatti
Sep 5, 2008·The Journal of Clinical Investigation·Hyung J ChunThomas Quertermous
Oct 16, 2008·Current Protein & Peptide Science·Nevena VeljkovicVeljko Veljkovic
Jan 20, 2009·Bioinformatics·Andrew M WaterhouseGeoffrey J Barton
Jan 25, 2011·Current Opinion in Pharmacology·Matthew C Zimmerman
Jul 8, 2011·Journal of Human Hypertension·J P Fisher, J F R Paton
Aug 9, 2011·Bioinformatics·Yoona KimNuno Bandeira
Jun 1, 2012·Expert Opinion on Drug Discovery·Nevena VeljkovicVeljko Veljkovic
Jul 24, 2012·Peptides·Baohua ChengQing Xin
Feb 22, 2013·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Tijana BojićEsma R Isenović
Mar 12, 2013·Progress in Cardiovascular Diseases·Satish R Raj, Samuel T Coffin
Sep 24, 2013·Clinica Chimica Acta; International Journal of Clinical Chemistry·Xiao-Hua YuChao-Ke Tang
Dec 11, 2013·Current Pharmaceutical Design·Niki KatsikiDimitri P Mikhailidis
Dec 3, 2014·Peptides·Yanjie YangQiang Chen
Jul 6, 2015·Trends in Pharmacological Sciences·Peiran YangAnthony P Davenport

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

AQVN
Jalview

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Current Protein & Peptide Science
Nevena VeljkovicVeljko Veljkovic
Zhonghua er ke za zhi. Chinese journal of pediatrics
Ping HuangHong-wei Wang
Sheng li ke xue jin zhan [Progress in physiology]
Ye JiaBing-Zhang Jie
Hellenic Journal of Cardiology : HJC = Hellēnikē Kardiologikē Epitheōrēsē
Michele Brignole
© 2021 Meta ULC. All rights reserved